Quality of life in non dialysis chronic kidney disease who receive and not receive erythropoiesis stimulating agent Anemia Quality of Life Hematinics Kidney Failure, Chronic
Conditions
Interventions
A medical prescription for erythropoietic stimulating agents (ESAs) and monitoring the hemoglobin levels at specific time points.
ESAs are medications that stimulate the production of red blood cells
s weight and medical condition. The hemoglobin levels are typically monitored at weeks 4, 12, and 24 to assess the effectiveness of the treatment and make any necessary adjustments to the ESA dosage.
s how you can interpret the monitoring schedule:
1. Week 4: After starting the ESA treatment, the patient'
s hemoglobin level is checked at the end of the fourth week to see if there is an appropriate response to the medication. If the hemoglobin level has increased to the desired range or shows improvemen
s overall condition, the healthcare provider might decide to continue the current dosage, adjust it, or consider alternative treatments.
3. Week 24, The final evaluation at the twenty-fourth week pro
s response to the ESA treatment. By this point, the healthcare provider can assess the long-term effects, and further adjustments to the dosage or tr
Receive erythropoiesis stimulating agent,Not receive erythropoietic stimulating agent
Sponsors
Phayao hospital
Eligibility
Sex/Gender
All
Age
15 Years to 100 Years
Inclusion criteria
Inclusion criteria: age more than 18 years old non dialysis chronic kidney disease stage V (eGFR < 15 ml/min/1.73m2) Hemoglobin 6.0-10.0 g/dL Transferrin saturation (TSAT) > 20% and ferritin > 100 mg/dL
Exclusion criteria
Exclusion criteria: Prior blood transfusion Pregnancy Breast feeding Iron deficiency anemia (TSAT < 20%, Ferritin < 100 mg/dL) Hemoglobinopathy Iron overload Hemochromatosis Upper Gastrointestinal bleeding/Acute bleeding in 6 months before Severe infection Any stage of malignancy Severe psychosis problem Severe systemic disease Uncontrolled hypertension within 1 month Cerebrovascular disease within 1 month
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Quality of life (EQ-5D-5L and KDQoL) 24 weeks after initiation score | — |
Secondary
| Measure | Time frame |
|---|---|
| Laboratory data 24 weeks after initiation amount | — |
Countries
Thailand
Contacts
Public ContactKanthitat Tanpradit
Phayao hospital
Outcome results
None listed